Children's medication
Medicines for children
The aim of the EU Regulation on Medicinal Products for Paediatric Use is to promote safer medicines for children:
- by developing medicines and pharmaceutical formulations for use in children,
- by ensuring that the medicines used in treatment of children are based on research of high quality and are appropriately authorised,
- by increasing and improving the available information on the effects of medicines in children, without subjecting children to unnecessary clinical trials.
The regulation lays down obligations for the pharmaceutical industry to study new products under development, and yet not authorised, also in children unless there are justified reasons for not doing so, and to report on all completed studies conducted in children, for medicines already on the market.
The National Agency for Medicines participates actively in various scientific committees of the European Medicines Agency (EMEA), among others also with regard to medicines for children, by e.g. coordinating of marketing authorisation procedures and by providing scientific advice.
More information:
Jaana Kallio, MD, PhD, Co-ordinating Senior Medical Officer, tel. +358-9-4733 4385
Ann Marie Kaukonen, PhD (Pharm), Senior Reseacher Medical Officer, tel. +358-9-4733 4472 (annmarie.kaukonen@nam.fi)
Merete Broms, Coordinator for Paediatric Medicines, tel. +358-9-4733 4397
firstname.surname@nam.fi
Members of the PDCO (Paediatric Committee)
Updated 9.2.2009